ALG-055009, Publications ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Ongoing Randomized, Double-Blind, Placebo-controlled Phase 2
ALG-055009, Publications Nonclinical Toxicology Profile of ALG-055009, a Novel and Potent Thyroid Hormone Receptor β Agonist, for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
ALG-055009, Publications Pharmacodynamics of Multiple Ascending Oral Doses of ALG-055009, a THR β Agonist, in Hyperlipidemic Subjects
ALG-055009, Publications Nonclinical Efficacy, Pharmacokinetic/Pharmacodynamic (PK/PD), and Toxicology Profile of ALG-055009, a Novel and Potent Thyroid Hormone Receptor β Agonist, for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
ALG-055009, Publications Safety, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Oral Doses Of ALG-055009, A Thyroid Hormone Receptor Beta Agonist, In Hyperlipidaemic Subjects And Relative Bioavailability/food Effect Of A Solid Formulation In Healthy Volunteers
ALG-055009, Publications Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with Hyperlipidaemia
ALG-055009, Publications Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta Agonist, in Hyperlipidaemic Subjects
ALG-055009, Publications Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta Agonist, for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with Hyperlipidaemia
ALG-055009, Publications Preclinical Pharmacokinetic Profiling of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of Nonalcoholic Steatohepatitis, and Prediction of its Human Pharmacokinetics
ALG-055009, Publications Development of a Novel Seven-Day Dosing Mouse Efficacy Model to Evaluate Thyroid Hormone Receptor Agonists for the Treatment of NASH